News
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, acknowledges that the ...
Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the ...
The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.
Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
Explore more
Some results have been hidden because they may be inaccessible to you
Show inaccessible results